About SIMPONI^® (golimumab)

A self-injectable biologic treatment

SIMPONI (golimumab) was developed to fit with patient needs and lifestyle, whilst continuing to improve functionality and disease outcomes. It is the first and only subcutaneous anti-TNF therapy with convenient once-monthly dosing from day 1 for RA, Ankylosing Spondylitis, Psoriatic Arthritis and a 4-weekly dosing schedule for Ulcerative Colitis.¹

To learn more please click the options below

SIMPONI Rheumatology

SIMPONI Gastroenterology

SmartJect^® features¹

1. Hidden needle – thin needle automatically deploys (first click), then retracts (second click), so your patients never have to see it.

2. Green safety sleeve – interlock prevents operation until the device is firmly pressed against injection site.

3. Activation button – patients press the raised part of the button to start the injection.

4. Large viewing window – makes it easy to see when the full dose of SIMPONI has been administered.

5. Expiration date – clearly printed on the side of the autoinjector.

6. Easy-to-grip shape – designed with patients in mind, with an easy-to-grip, oval-shaped body.

Important safety information

References

1. SIMPONI Summary of Product Characteristics.
2. SIMPONI Patient Information Leaflet.

Supporting documentation

SIMPONI 50 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet for Pre-filled Syringe | Patient Information Leaflet for Pre-filled Pen

SIMPONI 100 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet for Pre-filled Pen

GB-GOL-00112 | Date of Preparation: March 2019